Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART

AIDS

Volumn 20, Issue 10, 2006, Pages 1460-1462

  Amor, Aranzazu ^a   Toro, Carlos ^a   Jiménez, Victoria ^a   Simón, Ainhoa ^a   Ramos, Belén ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTERFERON; NEVIRAPINE; STAVUDINE; SYNTHETIC PEPTIDE; VIRUS RNA;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; ENZYME IMMUNOASSAY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SCREENING TEST; SEROLOGY; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; WESTERN BLOTTING;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; VIREMIA;

EID: 33745458491     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000233584.10209.43     Document Type: Article

References (13)

1. Kassutto S, Johnston M, Rosenberg E. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005; 40:868-873.
2. Hare C, Pappalardo B, Busch M, Karlsson A, Phelps B, Alexander S, et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006; 42:700-708.
3. Jurriaans S, Sankatsing S, Prins J, Schuitemaker H, Lange J, Van Der Kuyl A, et al. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS 2004; 18:1607-1608.
4. Morris L, Binley J, Clas B, Bonhoeffer S, Astill T, Kost R, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998; 188:233-245.
5. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy. Clin Infect Dis 2005; 40:e49-e54.
6. Binley J, Trkola A, Ketas T, Schiller D, Clas B, Little S, et al. The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:945-949.
7. Burton G, Keele B, Estes J, Thacker T, Gartner S. Follicular dendritic cell contributions to HIV pathogenesis. Semin Immunol 2002; 14:275-284.
8. Pierson T, McArthur J, Siliciano R. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18:665-708.
9. De Rossi A, Giaquinto C, Del Mistro A, Zamarchi R, Chieco-Bianchi L. Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child. AIDS 2000; 14:1284-1286.
10. Pham T, MacParland S, Mulrooney P, Cooksley H, Naoumov N, Michalak T. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78:5867-5874.
11. Radkowski M, Gallegos-Orozco J, Jablonska J, Colby T, Walewska-Zielecka B, Kubicka J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41:106-114.
12. Soriano V, Maida I, Nunez M, Garcia-Samaniego J, Barreiro P, Martin-Carbonero L, et al. Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. Antiviral Ther 2004; 9:987-992.
13. O'Connell R, Merritt T, Malia J, VanCott T, Dolan M, Zahwa H, et al. Performance of the OraQuick rapid antibody test for diagnosis of HIV type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy. J Clin Microbiol 2003; 41:2153-2155.